{ "schemaVersion": 2, "eyebrow": "Psychiatry", "title": "Generalized Anxiety Disorder", "summary": "Diagnose generalized anxiety disorder clinically after defining severity, functional impairment, comorbidity, substance contributions, and acute safety risk; then match treatment intensity to patient preference, access, and prior response using cognitive behavioral therapy, an SSRI, or an SNRI.", "seoDescription": "Physician guide to diagnosing and managing generalized anxiety disorder, including GAD-7 interpretation, comorbidity assessment, CBT, and medication selection.", "clinicalQuestion": "How should clinicians assess, stratify, and treat adults with suspected generalized anxiety disorder?", "specialty": "Psychiatry and Primary Care", "audience": "U.S. physicians and medical trainees", "tags": [ "generalized anxiety disorder", "GAD", "GAD-7", "cognitive behavioral therapy", "SSRI", "SNRI", "primary care psychiatry" ], "keyTakeaways": [ "Use the GAD-7 to quantify symptom burden and follow change, but establish GAD with a clinical diagnostic assessment rather than the questionnaire alone. Scores of 5, 10, and 15 correspond to mild, moderate, and severe symptom ranges. [4][24]", "Before treating presumed GAD, determine whether panic disorder, PTSD, obsessive-compulsive disorder, depressive illness, substance use, or another psychiatric condition is the primary driver of impairment. [16][19]", "For clinically significant GAD, offer cognitive behavioral therapy or pharmacotherapy with an SSRI or venlafaxine; treatment choice should account for patient preference, prior treatment, and access. [3][12][18]", "CBT can be delivered individually, in groups, or as guided self-help and is more effective than treatment as usual across these delivery formats. [3]", "Set remission rather than partial response as the treatment target because remission is associated with better functioning and lower relapse likelihood. [16][17]" ], "sections": [ { "id": "initial-assessment", "eyebrow": "First visit", "heading": "Confirm the clinical syndrome and identify competing priorities", "intro": "Use measurement to structure assessment, not to replace diagnostic interviewing.", "paragraphs": [ "Administer the seven-item GAD-7 at baseline to quantify current anxiety symptoms and functional burden. A score of 5, 10, or 15 marks mild, moderate, or severe symptom ranges, respectively; use serial scores to document response after treatment is initiated. The GAD-7 was developed to reflect GAD symptom criteria, but it is a screening measure rather than a stand-alone diagnosis. [4][24][8]", "Establish whether pervasive worry is the principal syndrome or whether anxiety is better explained by panic disorder, PTSD, obsessive-compulsive disorder, social anxiety disorder, specific phobia, acute stress disorder, or a depressive disorder. Anxiety disorders frequently coexist with depressive and other anxiety disorders, so identify the condition producing the greatest current impairment before choosing a disorder-specific psychotherapy or medication strategy. [16][19]", "Screen directly for suicidal ideation, self-harm risk, psychosis, manic or hypomanic symptoms, severe substance use, and inability to maintain basic safety. These findings change the care setting and should be addressed before a routine outpatient GAD treatment plan. Substance use can produce or worsen anxiety and sleep syndromes and may reveal another underlying psychiatric disorder requiring a different treatment approach. [14]" ], "bullets": [ "Document GAD-7 score at baseline and at follow-up visits; do not label a positive screen as diagnostic without clinical assessment. [4][8][24]", "Ask whether discrete panic episodes, trauma-linked re-experiencing or avoidance, compulsions, or circumscribed fears are more impairing than generalized worry; direct treatment toward the primary syndrome. [16][19]", "Obtain a medication, alcohol, cannabis, stimulant, sedative-hypnotic, and other substance history before attributing persistent anxiety solely to GAD. [14]" ], "subsections": [], "table": { "caption": "GAD-7 symptom-severity ranges for measurement-based follow-up. [24]", "columns": [ "GAD-7 score", "Symptom-severity range", "Clinical use" ], "rows": [ [ "5-9", "Mild [24]", "Use as a baseline measure; determine whether symptoms and impairment warrant active treatment. [24]" ], [ "10-14", "Moderate [24]", "Complete diagnostic and comorbidity assessment, then discuss structured CBT, pharmacotherapy, or both. [3][12][18][24]" ], [ "15 or higher", "Severe [24]", "Assess urgency, safety, functional compromise, comorbidity, and need for a higher-intensity treatment plan. [16][24]" ] ] } }, { "id": "treatment-selection", "eyebrow": "Initial treatment", "heading": "Select CBT, medication, or both according to severity and preference", "intro": "Treat to remission and reassess adequacy before declaring treatment failure.", "paragraphs": [ "Offer cognitive behavioral therapy as a first-choice treatment. A 2024 systematic review found CBT more effective than treatment as usual when delivered as individual therapy, group therapy, or guided self-help; delivery format can therefore be selected according to availability, cost, preference, and capacity for structured participation. [3]", "When pharmacotherapy is preferred, feasible, or clinically indicated, an SSRI is the usual first-line medication strategy; venlafaxine is also a first-choice pharmacologic option. Guidelines cited in primary care literature recommend CBT or pharmacotherapy with SSRIs or venlafaxine as initial treatment, and NICE guidance frames management around achieving complete symptom relief or remission. [12][16][18]", "Do not interpret lack of early complete remission as medication failure. Approximately one-half of patients achieve remission after 2 to 3 months of treatment in the cited synthesis, while symptom reduction within the first 2 weeks was associated with a greater likelihood of later response. Use early follow-up to assess tolerability, adherence, activation, sleep disruption, substance use, and emerging safety concerns, then reassess symptom trajectory with the GAD-7. [12]" ], "bullets": [ "Choose CBT when the patient prefers psychotherapy, wants to avoid medication exposure, or can engage in individual, group, or guided self-help treatment. [3]", "Choose an SSRI or venlafaxine when pharmacotherapy is preferred or psychotherapy access is limited; reassess symptom course and tolerability rather than switching solely because remission has not occurred in the first weeks. [12][18]", "Consider combined treatment pragmatically when symptoms remain functionally impairing despite an adequate trial of one modality or when comorbid depression or another anxiety disorder also requires treatment planning. [16][18]" ], "subsections": [], "table": { "caption": "Initial treatment choices for generalized anxiety disorder. [3][12][16][18]", "columns": [ "Option", "Evidence-supported role", "Selection considerations" ], "rows": [ [ "Cognitive behavioral therapy", "First-choice treatment; individual, group, and guided self-help CBT are more effective than treatment as usual. [3]", "Match delivery format to patient preference, access, and ability to engage in structured psychotherapy. [3]" ], [ "SSRI", "Usual first-line pharmacologic treatment for GAD. [12]", "Use when medication is preferred or indicated; monitor symptom change and adverse effects during the initial treatment course. [12]" ], [ "Venlafaxine", "Recommended pharmacologic first-choice option in guideline-based primary care treatment. [18]", "Consider alongside SSRIs when selecting pharmacotherapy based on prior response, tolerability, and patient preference. [18]" ] ] } }, { "id": "monitoring-and-nonresponse", "eyebrow": "Follow-up", "heading": "Measure response, verify treatment adequacy, and reframe nonresponse", "intro": "Persistent symptoms require reassessment of diagnosis, delivery, adherence, and comorbidity.", "paragraphs": [ "At each follow-up, repeat the GAD-7 and ask whether functional impairment, sleep disturbance, avoidance, work performance, and interpersonal functioning are improving. The intended endpoint is remission, not merely a lower questionnaire score, because remission is associated with improved functioning and lower relapse likelihood. [16][17]", "For an apparent medication nonresponse, first verify that the patient received a sustained, tolerable trial and is taking the prescribed agent. GAD commonly follows an episodic or waxing-and-waning course, and sustained treatment may be necessary; partial early symptom reduction can be informative but does not eliminate the need for continued monitoring. [12]", "For persistent impairment, reassess for depression, PTSD, panic disorder, obsessive-compulsive disorder, other anxiety disorders, and substance use. PTSD requires its own recognition and treatment pathway, while substance use may perpetuate anxiety symptoms or identify a different psychiatric syndrome. Escalate to psychiatric consultation when diagnosis remains uncertain, suicidality or bipolar-spectrum symptoms emerge, comorbidity is dominant, or repeated treatment attempts do not produce meaningful functional improvement. [14][16][19]" ], "bullets": [ "Track both GAD-7 change and restoration of function; neither alone fully defines recovery. [16][17][24]", "Before changing a medication strategy, evaluate adherence, adverse effects, duration of exposure, ongoing substance use, and whether the original diagnosis remains the best explanation for symptoms. [12][14][16]", "Reassess trauma exposure and PTSD symptoms when anxiety is linked to traumatic events, re-experiencing, avoidance, sleep problems, or concentration difficulty. [19]" ], "subsections": [], "table": { "caption": "Actionable causes of apparent GAD treatment failure. [12][14][16][19]", "columns": [ "Finding at follow-up", "Interpretation", "Next action" ], "rows": [ [ "No meaningful symptom change with inconsistent medication use or poor tolerability", "Treatment exposure may be inadequate. [12]", "Address barriers, adverse effects, and adherence before classifying the medication as ineffective. [12]" ], [ "Anxiety improves early but remains functionally impairing", "Partial response may justify continued measurement-based treatment and adjustment toward remission. [12][16]", "Repeat GAD-7, assess function, and review CBT engagement or medication tolerability before changing the plan. [12][16][24]" ], [ "Trauma-linked symptoms predominate", "PTSD may be the primary disorder rather than isolated GAD. [19]", "Use a PTSD-specific diagnostic and treatment assessment pathway. [19]" ], [ "Ongoing alcohol, sedative-hypnotic, stimulant, or other substance use", "Substances may worsen anxiety or indicate a co-occurring substance use disorder. [14]", "Treat the substance-related condition concurrently and reassess the anxiety syndrome. [14]" ], [ "Persistent diagnostic uncertainty, high risk, or repeated inadequate response", "Comorbidity or an alternative psychiatric disorder may be driving impairment. [14][16]", "Obtain psychiatric consultation and revise the diagnostic formulation. [14][16]" ] ] } }, { "id": "special-populations-and-care-setting", "eyebrow": "Context", "heading": "Adjust assessment and treatment planning for pregnancy and care setting", "intro": "Perinatal anxiety is common and requires individualized risk-benefit planning.", "paragraphs": [ "During pregnancy and the postpartum period, actively assess anxiety symptoms when clinically indicated: estimated GAD prevalence is 8.5% to 10.5% during pregnancy and 4.4% to 10.8% postpartum. Treatment selection should incorporate symptom severity, psychiatric history, prior response, concurrent depression, patient preference, and medication reproductive safety considerations. [1]", "Primary care can manage many patients with GAD using structured assessment, measurement-based follow-up, CBT referral or access pathways, and first-line pharmacotherapy. Refer or co-manage when severe risk, diagnostic complexity, bipolar-spectrum concerns, substance use disorder, PTSD, or failure of initial treatment prevents a clear and safe outpatient plan. [14][16][18][19]" ], "bullets": [ "In pregnancy, avoid assuming that anxiety symptoms are transient; quantify symptoms and assess functional impairment and psychiatric comorbidity. [1]", "If considering pregabalin after intolerance of SSRIs or SNRIs, review current pregnancy safety information and use individualized risk-benefit discussion. [17]" ], "subsections": [], "table": { "caption": "Care-setting decisions in adults with generalized anxiety symptoms. [14][16][18][19]", "columns": [ "Clinical context", "Appropriate treatment setting", "Reason to escalate" ], "rows": [ [ "Clear GAD without acute safety concerns or dominant comorbidity", "Primary care with CBT access and/or first-line pharmacotherapy. [18]", "Escalate if meaningful improvement is not achieved after reassessing treatment adequacy and diagnosis. [12][16]" ], [ "PTSD, substance use disorder, or another psychiatric syndrome drives impairment", "Condition-specific or integrated mental health care. [14][19]", "The primary disorder may require a different treatment pathway than isolated GAD. [14][19]" ], [ "Suicidality, psychosis, mania, severe functional compromise, or inability to maintain safety", "Urgent psychiatric evaluation or emergency-level assessment.", "Acute risk supersedes routine outpatient GAD management." ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "Screening for Anxiety Disorders in Adults: US Preventive ...", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jama/fullarticle/2806250", "authors": "jamanetwork.com", "host": "jamanetwork.com" }, { "number": 2, "title": "Expanding the Differential Diagnosis of Chronic Dizziness", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/484658", "authors": "jamanetwork.com", "host": "jamanetwork.com" }, { "number": 3, "title": "Psychotherapies for Generalized Anxiety Disorder in Adults", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2810866", "authors": "jamanetwork.com", "host": "jamanetwork.com" }, { "number": 4, "title": "Comparison of DASS-21, PHQ-8, and GAD-7 in a virtual ...", "detail": "www.cell.com", "url": "https://www.cell.com/heliyon/fulltext/S2405-8440(21)00578-8", "authors": "www.cell.com", "host": "www.cell.com" }, { "number": 5, "title": "Navigating the depths: A comprehensive narrative review ...", "detail": "www.cell.com", "url": "https://www.cell.com/heliyon/fulltext/S2405-8440(24)17420-8", "authors": "www.cell.com", "host": "www.cell.com" }, { "number": 6, "title": "Adjunctive fecal microbiota transplantation for major ...", "detail": "www.cell.com", "url": "https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(26)00210-6", "authors": "www.cell.com", "host": "www.cell.com" }, { "number": 7, "title": "Treating Cognitive Symptoms of Generalized Anxiety Disorder Using EMDR Therapy With Bilateral Alternating Tactile Stimulation", "detail": "spj.science.org", "url": "https://spj.science.org/doi/10.1891/EMDR-D-20-00026", "authors": "spj.science.org", "host": "spj.science.org" }, { "number": 8, "title": "Unravelling sex differences in the genetic... : Psychological Medicine", "detail": "journals.lww.com", "url": "https://journals.lww.com/00006826-202600000-00195", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 9, "title": "Medicine®", "detail": "journals.lww.com", "url": "https://journals.lww.com/md-journal/_layouts/15/oaks.journals/downloadpdf.aspx?an=00005792-202604170-00077", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 10, "title": "Epilepsy Comorbidities - Continuum", "detail": "journals.lww.com", "url": "https://journals.lww.com/continuum/abstract/2025/02000/a_multidisciplinary_approach_to_nonepileptic.11.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 11, "title": "The Role of Prediagnosis Audiovestibular...", "detail": "journals.lww.com", "url": "https://journals.lww.com/bsam/fulltext/2020/10000/the_role_of_prediagnosis_audiovestibular.9.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 12, "title": "Diagnosis of Generalized Anxiety Disorder - an overview", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/diagnosis-of-generalized-anxiety-disorder", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 13, "title": "Treatment resistant depression: Socio-demographic characteristics, comorbidity and treatment patterns from the All of Us Research Program", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S016503272501300X", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 14, "title": "THE MANAGEMENT OF TREATMENT RESISTANCE IN DEPRESSED PATIENTS WITH SUBSTANCE USE DISORDERS", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0193953X05702902", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 15, "title": "Treatment Resistant Depression - an overview", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/treatment-resistant-depression", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 16, "title": "Generalised anxiety disorder and panic disorder in adults: management - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK552847", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 17, "title": "Generalised anxiety disorder and panic disorder in adults ...", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/Guidance/cg113", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 18, "title": "Generalized anxiety disorder in primary care: mental health services use and treatment adequacy", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4618956", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 19, "title": "Overview | Post-traumatic stress disorder | Guidance | NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng116", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 20, "title": "Posttraumatic Stress Disorder in Children and Adolescents", "detail": "publications.aap.org", "url": "https://publications.aap.org/pediatricsinreview/article/47/7/361/208150/Posttraumatic-Stress-Disorder-in-Children-and", "authors": "publications.aap.org", "host": "publications.aap.org" }, { "number": 21, "title": "Therapist‐supported Internet cognitive behavioural therapy ...", "detail": "www.cochranelibrary.com", "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011565/references", "authors": "www.cochranelibrary.com", "host": "www.cochranelibrary.com" }, { "number": 22, "title": "Anxiety and Separation Disorders | Pediatrics In Review", "detail": "publications.aap.org", "url": "https://publications.aap.org/pediatricsinreview/article/32/10/440/32871/Anxiety-and-Separation-Disorders", "authors": "publications.aap.org", "host": "publications.aap.org" }, { "number": 23, "title": "Psychological therapies for panic disorder with or without ...", "detail": "www.cochranelibrary.com", "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011004.pub2/references", "authors": "www.cochranelibrary.com", "host": "www.cochranelibrary.com" }, { "number": 24, "title": "Generalized anxiety disorder questionnaire | Diagnosis - CKS", "detail": "cks.nice.org.uk", "url": "https://cks.nice.org.uk/topics/generalized-anxiety-disorder/diagnosis/generalized-anxiety-disorder-questionnaire", "authors": "cks.nice.org.uk", "host": "cks.nice.org.uk" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "Screening for Anxiety Disorders in Adults: US Preventive ...", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jama/fullarticle/2806250", "authors": "jamanetwork.com", "host": "jamanetwork.com", "snippet": "by US Preventive Services Task Force · 2023 · Cited by 131 — Generalized anxiety disorder has an estimated prevalence of 8.5% to 10.5% during pregnancy and 4.4% to 10.8% during the postpartum period.", "score": 0.34409124 }, { "number": 2, "title": "Expanding the Differential Diagnosis of Chronic Dizziness", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/484658", "authors": "jamanetwork.com", "host": "jamanetwork.com", "snippet": "by JP Staab · 2007 · Cited by 349 — Generalized anxiety: This category included generalized anxiety disorder, a condition identified by excessive worry about routine life events.", "score": 0.31798777 }, { "number": 3, "title": "Psychotherapies for Generalized Anxiety Disorder in Adults", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2810866", "authors": "jamanetwork.com", "host": "jamanetwork.com", "snippet": "by D Papola · 2024 · Cited by 139 — Cognitive behavior therapy is equally more effective than treatment as usual when delivered in the individual, group, or guided self-help", "score": 0.47884622 }, { "number": 4, "title": "Comparison of DASS-21, PHQ-8, and GAD-7 in a virtual ...", "detail": "www.cell.com", "url": "https://www.cell.com/heliyon/fulltext/S2405-8440(21)00578-8", "authors": "www.cell.com", "host": "www.cell.com", "snippet": "by L Peters · 2021 · Cited by 100 — The GAD-7 is a seven item scale used to assess symptoms of generalized anxiety disorder (GAD). The GAD-7 was developed to reflect symptom criteria of GAD", "score": 0.47241634 }, { "number": 5, "title": "Navigating the depths: A comprehensive narrative review ...", "detail": "www.cell.com", "url": "https://www.cell.com/heliyon/fulltext/S2405-8440(24)17420-8", "authors": "www.cell.com", "host": "www.cell.com", "snippet": "by NA Alkhaldi · 2025 · Cited by 7 — Generalized Anxiety Disorder-7 (GAD-7) Screening should occur at the time of epilepsy diagnosis, before 32(2):539-543. A brief measure for", "score": 0.35756806 }, { "number": 6, "title": "Adjunctive fecal microbiota transplantation for major ...", "detail": "www.cell.com", "url": "https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(26)00210-6", "authors": "www.cell.com", "host": "www.cell.com", "snippet": "by J Li · 2026 · Cited by 4 — A brief measure for assessing generalized anxiety disorder: the GAD-7 Arch.", "score": 0.29570305 }, { "number": 7, "title": "Treating Cognitive Symptoms of Generalized Anxiety Disorder Using EMDR Therapy With Bilateral Alternating Tactile Stimulation", "detail": "spj.science.org", "url": "https://spj.science.org/doi/10.1891/EMDR-D-20-00026", "authors": "spj.science.org", "host": "spj.science.org", "snippet": "### Measures\n\nTwo external evaluators administered screening measures and repeated measures at the first assessment and final assessment points. The screening measures consisted of two GAD specific tests.\n\n#### The Generalized Anxiety Disorder Anxiety Scale -7 items (GAD-7), in Its Argentinian Adapt", "score": 0.28799853 }, { "number": 8, "title": "Unravelling sex differences in the genetic... : Psychological Medicine", "detail": "journals.lww.com", "url": "https://journals.lww.com/00006826-202600000-00195", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Our results also support the use of a GAD-7 score ≥ 8 as a potential anxiety case definition. Most individuals meeting this cutoff (65.43%) also met at least one diagnostic anxiety definition in the UK Biobank, and the GAD-7 binary phenotype showed very strong genetic correlation with clinically def", "score": 0.42821008 }, { "number": 9, "title": "Medicine®", "detail": "journals.lww.com", "url": "https://journals.lww.com/md-journal/_layouts/15/oaks.journals/downloadpdf.aspx?an=00005792-202604170-00077", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "by R Aldala’een · 2026 — The Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 questionnaires were used to evaluate depression and anxiety after exposure", "score": 0.29228258 }, { "number": 10, "title": "Epilepsy Comorbidities - Continuum", "detail": "journals.lww.com", "url": "https://journals.lww.com/continuum/abstract/2025/02000/a_multidisciplinary_approach_to_nonepileptic.11.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "by MR Keezer · 2025 · Cited by 10 — Generalized Anxiety Disorder 7-Item Scale (GAD-7)61,62 Generalized anxiety disorder Seven-item questionnaire with a 4-level Likert scale; a score >6 is a", "score": 0.2918434 }, { "number": 11, "title": "The Role of Prediagnosis Audiovestibular...", "detail": "journals.lww.com", "url": "https://journals.lww.com/bsam/fulltext/2020/10000/the_role_of_prediagnosis_audiovestibular.9.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "by D Herdman · 2020 · Cited by 18 — GAD-7 = Generalized Anxiety Disorder Scale. , participants had significantly greater understanding. GAD-7 = Generalized Anxiety Disorder Scale;", "score": 0.28651395 }, { "number": 12, "title": "Diagnosis of Generalized Anxiety Disorder - an overview", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/diagnosis-of-generalized-anxiety-disorder", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Medications with proven efficacy in acute treatment of SAD include most SSRIs (escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline), venlafaxine, the monoamine oxidase inhibitors phenelzine and moclobemide, some benzodiazepines (bromazepam and clonazepam), some anticonvulsants (gabapen", "score": 0.67758125 }, { "number": 13, "title": "Treatment resistant depression: Socio-demographic characteristics, comorbidity and treatment patterns from the All of Us Research Program", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S016503272501300X", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "significant improvements were observed in the severity of anxiety (d=1.27, p<0.001), self-esteem (d=1.11, p=0.003), quality of life (d=1.42, p<0.001), and functioning (d=1.21, p=0.003). This unique psychotherapy shows promising preliminary results for treating individuals with TRD. Future trials sho", "score": 0.5198388 }, { "number": 14, "title": "THE MANAGEMENT OF TREATMENT RESISTANCE IN DEPRESSED PATIENTS WITH SUBSTANCE USE DISORDERS", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0193953X05702902", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "2 Depression may worsen the severity of substance use, increasing its deleterious effects over time. It has been shown consistently that patients with both depression and substance use syndromes have a poorer prognosis along various domains of outcome. In particular the combination of depression an", "score": 0.5183761 }, { "number": 15, "title": "Treatment Resistant Depression - an overview", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/treatment-resistant-depression", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "While medication combinations or switches as outlined in the STAR∗D trial are the most commonly utilized treatment strategies for TRD, these have limited effectiveness (Rush _et al._, 2006; Trivedi _et al._, 2006). Likewise, there are currently no rigorous studies supporting psychotherapy as monothe", "score": 0.5120832 }, { "number": 16, "title": "Generalised anxiety disorder and panic disorder in adults: management - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK552847", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "NICE Clinical Guidelines, No. 113\n\nThis guideline replaces CG22.\n\nThis guideline is the basis of QS23 and QS53.\n\n## Overview\n\nThis guideline covers the care and treatment of people aged 18 and over with generalised anxiety disorder (chronic anxiety) or panic disorder (with or without agoraphobia or ", "score": 0.7306941 }, { "number": 17, "title": "Generalised anxiety disorder and panic disorder in adults ...", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/Guidance/cg113", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "Last reviewed: 7 May 2024\n\nWe simplified the guideline by removing recommendations on general principles of care that are covered in other NICE guidelines (for example, the NICE guideline on service user experience in adult mental health).\n\nThis guideline updates and replaces NICE's guideline on anx", "score": 0.68748367 }, { "number": 18, "title": "Generalized anxiety disorder in primary care: mental health services use and treatment adequacy", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4618956", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "Patients with GAD often consult in the primary care setting and it is generally agreed that most cases should be treated in primary care . Clinical practice guidelines recommend either pharmacological treatments (e.g. SSRIs and venlafaxine) or cognitive behaviour therapy as first choice treatments ", "score": 0.59655124 }, { "number": 19, "title": "Overview | Post-traumatic stress disorder | Guidance | NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng116", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "You are here:\n\n# Post-traumatic stress disorder\n\n## Overview\n\nThis guideline covers recognising, assessing and treating post-traumatic stress disorder (PTSD) in children, young people and adults. It aims to improve quality of life by reducing symptoms of PTSD such as anxiety, sleep problems and diff", "score": 0.37421933 }, { "number": 20, "title": "Posttraumatic Stress Disorder in Children and Adolescents", "detail": "publications.aap.org", "url": "https://publications.aap.org/pediatricsinreview/article/47/7/361/208150/Posttraumatic-Stress-Disorder-in-Children-and", "authors": "publications.aap.org", "host": "publications.aap.org", "snippet": "this article provides a review of key clinical features of PTSD. Generalized Anxiety Disorder 7-Item. These measures assess for symptoms of", "score": 0.24931055 }, { "number": 21, "title": "Therapist‐supported Internet cognitive behavioural therapy ...", "detail": "www.cochranelibrary.com", "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011565/references", "authors": "www.cochranelibrary.com", "host": "www.cochranelibrary.com", "snippet": "Online treatments for mood and anxiety disorders in primary care. The quality of care for depressive and anxiety disorders in the United States.", "score": 0.2383467 }, { "number": 22, "title": "Anxiety and Separation Disorders | Pediatrics In Review", "detail": "publications.aap.org", "url": "https://publications.aap.org/pediatricsinreview/article/32/10/440/32871/Anxiety-and-Separation-Disorders", "authors": "publications.aap.org", "host": "publications.aap.org", "snippet": "Standard evidence-based anxiety disorder treatment guidelines recommend the use of CBT as first-line treatment for children who have anxiety", "score": 0.21388613 }, { "number": 23, "title": "Psychological therapies for panic disorder with or without ...", "detail": "www.cochranelibrary.com", "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011004.pub2/references", "authors": "www.cochranelibrary.com", "host": "www.cochranelibrary.com", "snippet": "Other current comorbid diagnoses, including unipolar depression and other anxiety disorders, were allowed unless they were of primary clinical concern.", "score": 0.15081534 }, { "number": 24, "title": "Generalized anxiety disorder questionnaire | Diagnosis - CKS", "detail": "cks.nice.org.uk", "url": "https://cks.nice.org.uk/topics/generalized-anxiety-disorder/diagnosis/generalized-anxiety-disorder-questionnaire", "authors": "cks.nice.org.uk", "host": "cks.nice.org.uk", "snippet": "The generalized anxiety disorder questionnaire (GAD-7) consists of seven questions. Scores of 5, 10, and 15 are taken as cut-off points for mild, moderate, and", "score": 0.73596483 } ], "publishedAt": "2026-08-21T02:42:04.936831+00:00", "updatedAt": "2026-08-21T02:42:04.936831+00:00", "readingMinutes": 5, "slug": "generalized-anxiety-disorder" }